UBS Group
OACC

UBS Group’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

UBS Group’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9K Sell
1,580
-70,183
-98% -$747K ﹤0.01% 8254
2026
Q1 		$759K Sell
71,763
-28,718
-29% -$306K ﹤0.01% 5765
2025
Q4 		$1.06M Buy
100,481
+1,760
+2% +$18.6K ﹤0.01% 5511
2025
Q3 		$1.04M Buy
98,721
+98,711
+987,110% +$1.03M ﹤0.01% 5545
2025
Q2 		$105 Buy
+10
New +$104 ﹤0.01% 9997

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's OACC Position: Q2 2026 in Review

UBS Group reduced its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 98% in Q2 2026, selling an estimated $747K and leaving 1,580 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8254.

UBS Group first reported a position in OACC in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.06M in Q4 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • UBS Group held 1,580 shares of Oaktree Acquisition Corp III Life Sciences worth $16.9K as of Q2 2026.
  • UBS Group sold 70,183 Oaktree Acquisition Corp III Life Sciences shares in Q2 2026, an estimated $747K.
  • Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8254 holding.
  • UBS Group first reported a position in Oaktree Acquisition Corp III Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • UBS Group's Oaktree Acquisition Corp III Life Sciences position peaked at $1.06M in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.